Australia's Authorised Prescriber Scheme: What 134 Patients Reveal About a Real-World Psychedelic Programme

Three years after Australia became the first country to reschedule psilocybin and MDMA for prescribed clinical use, we now have something other than press releases: real numbers from a real regulator. They are smaller than the field anticipated and more important than they look. Outside the United States, this is currently the only place where psychedelic-assisted therapy is being delivered at scale outside trials, with mandatory prospective adverse-event reporting to the TGA and to state ethics committees. Australia is, in effect, the world's de-risking test bed.

What the data shows

The pace is slow and structural. Fewer than 100 patients accessed treatment in the first 18 months of the AP scheme; growth came in mid-2025 once referral pathways from GPs, psychiatrists, therapists and insurers stabilised. By year-end 2025, MDMA-assisted therapy and psilocybin-assisted therapy were available in six of eight states and territories, including some regional areas — a meaningful geographic spread for a country of 26 million people, but still concentrated. The bottleneck is not the drug; it is psychiatrist and therapist time. With current protocols modelled on trial conditions, a three-dose MDMA programme runs ~AUD $30,000, almost entirely as labour cost.

Reimbursement is the variable to watch. Both private and public payors expanded coverage in 2025 — first MDMA in June, then psilocybin. That signal matters more than patient counts: payors do not move when they expect a tort liability problem, and they did move. Psychedelic Alpha estimates Australia could plausibly treat 1,000 MDMA patients in 2026, but the structural maths is sobering: that scale would require ~100+ AP psychiatrists (currently 30) and a therapist workforce in the low thousands. There is also a TGA submission in progress to extend psilocybin to end-of-life distress.

For your practice

For clinicians outside Australia, three signals are actionable now. First, the Australian protocols are publicly accessible templates; if your jurisdiction follows (Czechia, parts of the EU, Oregon's Measure 109 framework, and a likely post-Lykos US in 2027+), the labour-intensive delivery model is what gets imported, not just the molecule. Plan for staffing now, not after approval. Second, the safety signal — zero SAEs in 87 MDMA patients, structured HREC reporting — is the kind of evidence that will be cited in EMA and FDA dossiers; if you advise patients on referral abroad, you can speak to it from the data, not the marketing. Third, the AP scheme remains restricted to PTSD and TRD; for patients outside those indications, the answer is still "trial enrolment or wait", and that conversation should be honest about timeline.

The cultural-training piece in Australia's 2026 roadmap — embedding it for all PAT therapists rather than as an add-on — is also worth importing into supervision discussions, regardless of whether your patients ever touch a psychedelic. Cultural responsiveness in non-ordinary-states work is not a soft skill; it is a risk-management requirement.